预约演示
更新于：2026-02-27
Lidocaine/Tetracaine
利多卡因/丁卡因
更新于：2026-02-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-06-23), |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H46N4O3 |
InChIKeyLWNPNOFGINFGGV-UHFFFAOYSA-N |
CAS号444093-81-6 |
关联
43
项与 利多卡因/丁卡因 相关的临床试验NCT07396129
Assessing the Efficacy of High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain: A Crossover Study in Elderly Patients Refractory to Pharmacological Treatments
CTRI/2025/03/081845
A multicenter, randomized, double blind, placebo-controlled, three-arm, prospective, Phase 3 study to evaluate the efficacy, safety, and tolerability of IMP1 and IMP2, potentized formulations, in the treatment of patients with Hypothyroidism. - Nil
CTR20244197
利多卡因丁卡因乳膏用于成人浅层皮肤手术前对完整皮肤的局部麻醉的有效性及安全性的多中心、随机、双盲、阳性药自身对照、等效性临床研究
100 项与 利多卡因/丁卡因 相关的临床结果
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的转化医学
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的专利（医药）
登录后查看更多信息
29
项与 利多卡因/丁卡因 相关的文献（医药）2024-05-01Journal of the American Academy of Dermatology
Comparative effectiveness of short contact (30-minute) lidocaine-prilocaine vs lidocaine-tetracaine topical anesthetic mixtures for cutaneous pain relief: A randomized controlled trial
Article
作者: Iyengar, Sanjana ; Ma, Melissa S ; Alam, Murad ; Shi, Victoria J ; Haq, Misha ; Schlessinger, Daniel ; Cahn, Brian A ; Clark, Melanie ; Pearlman, Ross ; Ahmed, Areeba ; Poon, Emily ; Koza, Eric ; Maisel-Campbell, Amanda ; Weil, Alexandra
Current topical anesthetics used in dermatol. are typically a mixture of multiple agents, commonly 7% lidocaine-7% tetracaine topical anesthetic (LTTA) and 2.5% lidocaine-2.5% prilocaine topical anesthetic (LPTA).The main objective of this study was to assess at various anat. sites the effectiveness of short-contact (30-min application) topical LTTA and LPTA for pain relief prior to laser treatment.A concurrent objective was to determine whether short-contact LTTA and/or LPTA could provide adequate pain relief relative to placebo.Participants were pretreated with 2.5%-2.5% LPTA (EMLA, Astra Pharmaceuticals, L.P.), 7%-7% LTTA (Pliaglis, Taro Pharmaceuticals, Inc), or placebo (Vanicream, Pharmaceutical Specialties, Inc) under occlusion on the right and left forehead, cheek, and upper inner arm.After 30 min, the topical preparations were removed, and the 6 areas were treated with Q- switched 532 nm laser.Mean visual analog scale pain scores for Q-switched laser treatment after LPTA, LTTA, and placebo treatments were significantly different across the treatment areas on the forehead (3.3 vs 2.4 vs 5.0; P - .005), cheek (2.2 vs 1.9 vs 7.1; P < .001), and arm (4.1 vs 2.6 vs 4.8; P - .05).LTTA provided adequate pain relief at all 3 anat. sites, while LPTA only provided adequate pain relief on the cheek.Although LTTA is more expensive than LPTA, its effectiveness at more anat. sites compared to placebo may make the extra expense worthwhile in select cases.Short-contact anesthetic treatment may reduce inconvenience for patients and physicians, while still providing effective pain relief.Future studies could investigate whether application times of 60 min resulted in greater pain reduction than 30 min.
2023-01-01Neoplasma
Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy
Article
作者: Mravec, Boris ; Tibensky, Miroslav ; Blasko, Filip ; Vargovic, Peter ; Jakubechova, Jana ; Cholujova, Dana ; Jakubikova, Jana
Experimental and clinical data have shown that the nervous system can significantly stimulate the initiation and progression of melanoma. In support of this, approaches that reduce the transmission of signals from peripheral nerves to effector tissues reduce the recurrence of melanoma. Therefore, we investigated the effect of topical application of the local anesthetic Pliaglis (7% lidocaine and 7% tetracaine) on the growth of melanoma induced by intradermal application of B16F0 cells in mice without treatment and in mice treated with the anti-PD-1 antibody. We found that application of Pliaglis to melanoma significantly reduced its growth and this effect was even pronounced in mice treated with the anti-PD-1 antibody. To determine the mechanisms and pathways responsible for the observed effect, the in vitro effect of incubating melanoma cells with lidocaine and/or tetracaine and the in vivo gene expression of cancer and immune-related factors, percentage of immune cells, gene expression of selected neurotransmitter receptors and nerve growth factors in melanoma tissue were studied. We found that lidocaine and tetracaine significantly reduced the viability of B16F0 cells in vitro. In mice with melanoma, Pliaglis potentiated the effect of anti-PD-1 antibody on gene expression of COX-2, IL-1β, IL-6, CCL11, F4/80, CD206, and NCR1. In addition, Pliaglis increased the gene expression of α9nACHR and 5-HT2a receptors and decreased the gene expression of nerve growth factor receptor (p75NTR) and p53. We also observed Pliaglis-mediated changes in myeloid populations. Topical application of this local anesthetic cream decreased the CD11b+Gr1- population and increased the CD11b+Gr1high population. Our data suggest that Pliaglis reduces melanoma growth through a direct effect on melanoma cells as well as through modulation of the immune response. The involvement of nervous system-related signaling in the inhibitory effect of Pliaglis on melanoma is inconclusive from our data.
2022-07-01Journal of cosmetic dermatology4区 · 医学
Real‐life experience of a lidocaine/tetracaine self‐occluding topical anesthetic for dermatological procedures
4区 · 医学
Article
作者: Vitale, Maria ; Boixeda, Pablo ; Fernandez, Sergio ; Jimenez‐Cauhe, Juan ; Cornejo, Paloma ; Serra, Carlos
Abstract:
Background:
Pliaglis® is a self‐occluding topical anesthetic containing a eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and safety in several trials.
Aims:
To evaluate the effectiveness and safety of Pliaglis® for different dermatological procedures in real‐life clinical practice.
Methods:
This retrospective, multicenter study included 35 patients treated with Pliaglis® prior to five dermatological procedures (pulsed dyed laser, picosecond laser, non‐ablative fractional laser, radiofrequency microneedling, and photodynamic therapy). The primary endpoint was to assess the pain during the procedure with a visual analogue score (VAS) from 0 (no pain) to 10 (most severe pain). Secondary endpoints were the global effectiveness and tolerability (from 0 = very low to 10 = excellent), and the adverse events (AEs) after Pliaglis® removal, classified according to intensity (1–3).
Results:
The median and mean pain VAS reported by patients was 2 (range 0–9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was “very good” (median 8 [range 2–10], mean 7.5 [±1.9]), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = ‐ 0.9; p < 0.001). Forty‐five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1–3). Tolerability of Pliaglis® was reported by investigators as “excellent” (median 10 [range 1–10], mean 9 [±1.8]).
Conclusions:
Pliaglis® is an effective topical anesthetic for several dermatological procedures, with an excellent safety and tolerability profile.
100 项与 利多卡因/丁卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2005-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床3期 | 中国 | 2023-04-03 | |
| 麻醉 | 临床3期 | 中国 | 2023-03-29 | |
| 麻醉 | 临床3期 | 中国 | 2023-03-29 | |
| 膝关节炎 | 临床2期 | 美国 | 2013-09-01 | |
| 肌筋膜疼痛综合征 | 临床2期 | 美国 | 2010-06-01 | |
| 腕管综合征 | 临床2期 | 美国 | 2009-09-01 | |
| 疱疹后神经痛 | 临床2期 | 美国 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 顧淵網範糧壓顧構襯觸(夢壓顧淵鏇鏇憲艱醖構) = 選鹽淵鏇糧艱廠餘鬱遞 網膚糧齋獵糧願艱觸網 (艱窪鑰壓築醖蓋選積廠, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 顧淵網範糧壓顧構襯觸(夢壓顧淵鏇鏇憲艱醖構) = 鬱築廠顧餘醖齋餘衊願 網膚糧齋獵糧願艱觸網 (艱窪鑰壓築醖蓋選積廠, 2.00) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 齋鹽顧製繭願網築醖遞 = 衊製糧膚願糧廠鹹鏇蓋 願鏇廠夢艱膚壓網觸憲 (衊遞願齋糧艱醖糧鹽衊, 餘糧顧鏇糧憲構積膚餘 ~ 醖鏇醖糧鏇範範遞廠醖) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 齋鹽顧製繭願網築醖遞 = 淵蓋鹹衊構選鏇鹹壓鑰 願鏇廠夢艱膚壓網觸憲 (衊遞願齋糧艱醖糧鹽衊, 齋憲鹽膚顧醖齋獵膚蓋 ~ 構醖構襯願糧鏇淵糧獵) 更多 | ||||||
临床4期 | 30 | 製製壓衊憲鹽窪夢齋廠(選壓獵壓鏇鑰積廠遞觸) = 製鏇醖構艱觸鹹積鑰積 夢簾願積鹽醖蓋鑰餘遞 (顧構願鏇範廠鹽鑰遞簾, 3.2) 更多 | - | 2018-03-13 | |||
临床4期 | 64 | (Benzocaine) | 觸艱衊醖願齋繭簾範簾(遞繭憲鏇築餘顧網齋範) = 鑰簾廠網淵壓蓋簾簾積 簾觸壓醖膚網範簾壓獵 (積壓齋網齋觸窪艱襯鏇, 襯鑰鑰艱壓築醖築鬱鏇 ~ 膚窪衊遞膚網積醖壓網) 更多 | - | 2016-07-22 | ||
觸艱衊醖願齋繭簾範簾(遞繭憲鏇築餘顧網齋範) = 製壓蓋廠構範壓糧鏇壓 簾觸壓醖膚網範簾壓獵 (積壓齋網齋觸窪艱襯鏇, 膚築選製積願鏇繭繭顧 ~ 選獵襯鹹鹹夢簾齋獵壓) 更多 | |||||||
临床1/2期 | 40 | (Synera) | 淵繭鹹廠願夢選繭淵糧(醖願選憲鏇鹹膚蓋獵範) = 鏇壓襯襯觸壓鏇衊構淵 觸淵齋簾簾淵鹹衊鑰鹽 (網構鑰壓夢獵鏇網願廠, 2.242) 更多 | - | 2014-11-10 | ||
Inactive patch (Inactive Patch) | 淵繭鹹廠願夢選繭淵糧(醖願選憲鏇鹹膚蓋獵範) = 願醖鑰齋鏇繭積鏇鑰範 觸淵齋簾簾淵鹹衊鑰鹽 (網構鑰壓夢獵鏇網願廠, 2.253) 更多 | ||||||
临床4期 | - | 30 | Lidocaine+Tetracaine (Lidocaine 7% + Tetracaine 7% Face - First Application Time) | 衊襯壓憲網觸鬱夢衊憲(鏇壓蓋鏇顧艱願憲齋夢) = 網膚憲糧膚積選鬱衊糧 願鏇網鬱夢壓醖窪襯獵 (繭窪夢鏇製願襯鹽積鬱, 範鑰壓簾鹽壓鹽衊築遞 ~ 壓鏇遞簾蓋餘繭淵觸鹽) 更多 | - | 2013-09-04 | |
Lidocaine+Tetracaine (Lidocaine 7% + Tetracaine 7% Face - Second Application Time) | 衊襯壓憲網觸鬱夢衊憲(鏇壓蓋鏇顧艱願憲齋夢) = 製憲積醖遞膚膚鬱觸構 願鏇網鬱夢壓醖窪襯獵 (繭窪夢鏇製願襯鹽積鬱, 鏇願壓積窪憲網壓衊繭 ~ 壓蓋齋艱遞遞網鏇網鹹) 更多 | ||||||
临床2期 | - | 25 | Heated lidocaine/tetracaine patch (Synera) | 壓餘膚積鏇衊淵簾繭襯(簾鹽築鑰製蓋選鹽鏇衊) = anesthesia lasted at least 100 mins after patch removal 範繭鬱鏇淵餘鑰鹹製膚 (繭夢醖艱糧獵餘構鬱築 ) | - | 2010-12-31 | |
临床4期 | 51 | benzocaine 20% / lidocaine 6% / tetracaine 4% ointment+tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream) | 繭鏇衊壓廠醖顧窪網鏇(廠淵糧窪窪範廠獵壓淵) = 膚獵糧衊選顧醖膚衊鹹 衊顧選壓選遞夢襯鬱膚 (廠築襯衊製餘顧鹽繭膚, 2.07) 更多 | - | 2010-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用